Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342548 | 0.83 | OPRD1 (0.55) | OPRD1CYP3A4CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL18785421 | 0.81 | OPRM1 (0.49) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL18785469 | 0.81 | OPRM1 (0.48) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL18785448 | 0.80 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL13317173 | 0.78 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL2142315 | 0.78 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL69083 | 0.78 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL2142366 | 0.77 | CYP3A4 (0.42) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL1489316 | 0.77 | OPRM1 (0.50) | OPRM1OPRK1OPRL1OPRD1CYP3A4 | |
| SCHEMBL1742229 | 0.77 | OPRM1 (0.71) | OPRM1OPRK1OPRL1OPRD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | OPRM1 2864/4885OPRK1 2582/4885OPRL1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.